Accelerate Diagnostics (MEX:AXDX) Beta: -1.5398 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AXDX Accelerate Diagnostics Inc MEX:AXDX
12 GF Score
Price MXN1.75
View Full Analysis

What is Accelerate Diagnostics Beta?

Accelerate Diagnostics MEX:AXDX 12 Beta is -1.5398 as of Sep. 09, 2026. GuruFocus rates MEX:AXDX with a GF Score™ of 12/100.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-09), Accelerate Diagnostics's Beta is -1.5398.


Accelerate Diagnostics  (MEX:AXDX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Accelerate Diagnostics Beta Related Terms


Accelerate Diagnostics Beta Historical Data

* Premium members only.

The historical data trend for Accelerate Diagnostics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accelerate Diagnostics Beta Chart

Accelerate Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.85 -0.19 -0.23

Accelerate Diagnostics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 0.01 -0.23 -0.20 -0.23

MEX:AXDX vs MSIU, BIOLQ, AFIB: Beta Comparison

For the Medical Devices subindustry, Accelerate Diagnostics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerate Diagnostics Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Beta distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's Beta falls into.


MEX:AXDX
12GF Score
Accelerate Diagnostics Inc MEX:AXDX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accelerate Diagnostics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -1.5398 mean?
Accelerate Diagnostics (MEX:AXDX) has a Beta of -1.5398 as of Sep. 09, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Beta too high?
Accelerate Diagnostics' current Beta is -1.5398. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Beta compare to MSIU and BIOLQ?
Accelerate Diagnostics' Beta of -1.5398 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Accelerate Diagnostics and its competitors. Accelerate Diagnostics's current Beta is -1.5398. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Beta of -1.5398. The current Beta is -1.5398. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Beta is -1.5398 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accelerate Diagnostics Business Description

Address 3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score

Get the complete analysis for MEX:AXDX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1.75
Price